Diagnostic performance of bone scintigraphy and 11C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer

被引:15
|
作者
Garcia, J. R. [1 ]
Moreno, C. [1 ]
Valls, E. [1 ]
Cozar, P. [1 ]
Bassa, P. [1 ]
Soler, M. [1 ]
Alvarez-Moro, F. J. [1 ]
Moragas, M. [1 ]
Riera, E. [1 ]
机构
[1] Unidad PET CETIR ERESA, Barcelona, Spain
来源
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR | 2015年 / 34卷 / 03期
关键词
Bone scintigraphy; C-11-Choline PET/CT; Bone metastases; Biochemical recurrence; Prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; F-18-FLUORIDE PET; F-18-FDG PET/CT; DISEASE; SPECT; ONCOLOGY; RELAPSE; CT;
D O I
10.1016/j.remn.2014.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To compare bone scan (BS) with C-11-Choline PET/CT for the detection of bone metastases in patients with biochemical recurrence of prostate cancer (PC). Material and Methods: A total of 169 patients with biochemical recurrence of PC(PSA:2.4-58 ng/ml) who were referred for both exams (0-15 days-in-between) were included. Lesion-detection-rate per patients and lesions were analyzed for both BS and C-11-Choline PET/CT. Metastasis diagnosis was reached by: biopsy, CT/F-18-Fluoride PET/MRI confirmation, or evidence of progression in subsequent imaging procedures. Results: A total of 91 lesions were found to be active in BS and/or C-11-choline PET/CT (40 patients), with 78 of which were metastatic. BS detected 38 blastic, 2 lytic and 10 non-CT-evident lesions. C-11-Choline PET/CT detected 41 blastic, 4 lytic and 29 non-CT-evident lesions. BS and C-11-Choline PET/CT sensitivities were 65.4% and 96.1%; specificities ere 38.5 and 92.3% (chi(2) 8.27, p < 0.04). Both imaging techniques were negative in 118 patients. Tracer avid lesions were found in 51 patients: with 30/51 being BS and C-11-Choline PET/CT concordant; in 21/51 patients had discordant lesions (kappa 0.712, p = 0.00). Lesions were absolutely discordant in 10/19 patients,: 5 FN BS, 2 FP BS (degenerative changes: dysplasia), 1 FN C-11-Choline PET/CT (blastic), 1 FP C-11-Choline PET/CT (degenerative), 1 out of field-of-view lesion with C-11-Choline PET/CT (tibia alone). C-11-Choline PET/CT showed extraosseous involvement in 26/51 patients with bone metastases: 9 local recurrences, 5 infra-diaphragmatic-lymph-nodes, 2 supra-diaphragmatic, 5 local and infra-diaphragmatic, 4 infra- and supra-diaphragmatic, 1 supra-diaphragmatic and lung metastases. Conclusion: C-11-Choline PET/CT yielded better sensitivity and specificity than BS for the detection of bone involvement in patients with biochemical recurrence of PC and allowed extraosseous restaging, with an impact in the clinical management of these patients. (C) 2014 Elsevier Espana, S.L.U. and SEMNIM. All rights reserved.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 50 条
  • [21] Effectiveness of 11C-choline PET/CT in prostate cancer surveillance
    Martinez-Rodriguez, I.
    de Arcocha-Torres, M.
    Gomez de la Fuente, F. J.
    Jimenez-Bonilla, J.
    Sanchez-Salmoen, A.
    Martinez-Amador, N.
    Mendi-Barcina, V.
    Andres-Pacheco, J.
    Gutierrez-Gonzalez, A.
    Pombo-Lopez, M.
    Bota-Bota, A.
    Rodil-Gallego, M.
    Garcia-Ruiz, A.
    Quirce, R.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (02): : 93 - 99
  • [22] Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer
    Garcia, J. R.
    Ponce, A.
    Canales, M.
    Ayuso, J.
    Moragas, M.
    Soler, M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2014, 33 (01): : 28 - 31
  • [23] Clinical Indications of 11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse
    Picchio, Maria
    Castellucci, Paolo
    THERANOSTICS, 2012, 2 (03): : 313 - 317
  • [24] 11C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer
    Garcia, J. R.
    Romera, N.
    Cozar, M.
    Soler, M.
    Moragas, M.
    Escobar, M.
    ACTAS UROLOGICAS ESPANOLAS, 2015, 39 (04): : 259 - 263
  • [25] [11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
    Rinnab, Ludwig
    Simon, Joerg
    Hautmann, Richard E.
    Cronauer, M. V.
    Hohl, Kathrin
    Buck, Andreas K.
    Reske, Sven N.
    Mottaghy, Felix M.
    WORLD JOURNAL OF UROLOGY, 2009, 27 (05) : 619 - 625
  • [26] Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: A meta-analysis
    Treglia G.
    Vigneri C.
    Sadeghi R.
    Evangelista L.
    Ceriani L.
    Giovanella L.
    Clinical and Translational Imaging, 2015, 3 (2) : 133 - 140
  • [27] Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT
    Meltem Caglar
    Murat Tuncel
    Egemen Yildiz
    Erdem Karabulut
    Annals of Nuclear Medicine, 2020, 34 : 932 - 941
  • [28] Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis
    Zhou, Jing
    Gou, Zhengxing
    Wu, Renhui
    Yuan, Yuan
    Yu, Guiquan
    Zhao, Yigang
    SKELETAL RADIOLOGY, 2019, 48 (12) : 1915 - 1924
  • [29] Influence of 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer
    Souvatzoglou, Michael
    Krause, Bernd J.
    Puerschel, Anja
    Thamm, Reinhard
    Schuster, Tibor
    Buck, Andreas K.
    Zimmermann, Frank
    Molls, Michael
    Schwaiger, Markus
    Geinitz, Hans
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 (02) : 193 - 200
  • [30] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Bernhard Scher
    Michael Seitz
    Wolfram Albinger
    Reinhold Tiling
    Michael Scherr
    Hans-Christoph Becker
    Michael Souvatzogluou
    Franz-Josef Gildehaus
    Hans-Jürgen Wester
    Stefan Dresel
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 45 - 53